Martin Edwards
Director/Board Member at INOZYME PHARMA, INC.
Net worth: 2 M $ as of 2024-03-30
Network origin in Martin Edwards first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
The Royal College of Physicians
117
| College/University | Other Consumer Services | 117 |
| Subsidiary | Pharmaceuticals: Major | 32 | |
| Public Company | Pharmaceuticals: Major | 28 | |
| Public Company | Pharmaceuticals: Major | 25 | |
| Public Company | Pharmaceuticals: Major | 20 | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA.
16
| Subsidiary | Biotechnology | 16 |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark.
16
| Operating Division | Investment Managers | 16 |
Royal College of General Practitioners
 Royal College of General Practitioners Other Consumer ServicesConsumer Services The Royal College of General Practitioners is a professional membership body for family doctors in the UK and overseas. The non-profit company is based in London, UK and has subsidiaries in the United Kingdom. The British company is committed to improving patient care and clinical standards. The RCGP offers a fellowship program, which is the highest level of membership and exemplifies their motto "cum scientia caritas". The company also provides accreditation for high-quality resources and activities relevant to general practitioners. The Daffodil Standards is a free, evidence-based framework to help practices self-assess and consistently offer the best end of life and bereavement care. The RCGP represents the interests of established GPs and acts as a conduit for local matters to be raised at national meetings.
15
| Non-Profit Organization | Other Consumer Services | 15 |
| Subsidiary | Biotechnology | 14 | |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.
7
| Holding Company | Biotechnology | 7 |
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom.
6
| Holding Company | Pharmaceuticals: Other | 6 |
| Public Company | Pharmaceuticals: Major | 6 | |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA.
5
| Holding Company | Pharmaceuticals: Major | 5 |
| Public Company | Pharmaceuticals: Major | 5 | |
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Nuvelution Pharma, Inc.
 Nuvelution Pharma, Inc. BiotechnologyHealth Technology Nuvelution Pharma, Inc. provides solutions for R&D companies in the pharmaceutical and biotech industries. The firm leverages its knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources, making this model an essential tool for pharma and biotech companies to bring products to the market. The company was founded by Sanford S. Zweifach and is headquartered in South San Francisco, CA.
4
| Holding Company | Biotechnology | 4 |
ReNeuron Ltd.
 ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom.
3
| Subsidiary | Biotechnology | 3 |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ.
3
| Subsidiary | Biotechnology | 3 |
Vantia Ltd.
 Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA.
1
| Extinct | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Martin Edwards via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Comptroller/Controller/Auditor Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK KGAA | Pharmaceuticals: Major | Chief Investment Officer Comptroller/Controller/Auditor | |
| BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Chairman | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| OXFORD BIOMEDICA PLC | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| National University of Singapore | College/University | Graduate Degree Doctorate Degree Corporate Officer/Principal | |
| University of Oxford | College/University | Undergraduate Degree Corporate Officer/Principal Undergraduate Degree Doctorate Degree Doctorate Degree Undergraduate Degree | |
| Imperial College London | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree | |
| The University of Manchester | College/University | Doctorate Degree Undergraduate Degree | |
| University of Glasgow | College/University | Doctorate Degree Doctorate Degree | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Undergraduate Degree Masters Business Admin Undergraduate Degree Undergraduate Degree | |
| McGill University | College/University | Undergraduate Degree Doctorate Degree | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Bentley University | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree | |
Kyowa Kirin International Plc
 Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| The University of Edinburgh | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree Graduate Degree Graduate Degree | |
| University of Michigan | College/University | Undergraduate Degree Masters Business Admin Doctorate Degree Undergraduate Degree | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| ENANTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Parkway Group Healthcare Pte Ltd.
 Parkway Group Healthcare Pte Ltd. Hospital/Nursing ManagementHealth Services Parkway Group Healthcare Pte Ltd. provides general and specialized health care services. It operates a chain of private hospitals across South East Asia and the United Kingdom. The company is headquartered in Singapore | Hospital/Nursing Management | Director/Board Member Corporate Officer/Principal | |
| ENDOCYTE, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University College London | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Graduate Degree | |
| Henley Management College | College/University | Masters Business Admin Masters Business Admin | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Director/Board Member | |
American College of Cardiology Foundation
 American College of Cardiology Foundation Medical/Nursing ServicesHealth Services American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC. | Medical/Nursing Services | Corporate Officer/Principal Corporate Officer/Principal | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Undergraduate Degree Masters Business Admin | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member | |
| REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Alchemab Therapeutics Ltd.
 Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom. | Biotechnology | Chief Executive Officer Director/Board Member | |
| KRONOS BIO, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| Tuck School of Business at Dartmouth | College/University | Masters Business Admin Masters Business Admin | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Director/Board Member Chief Executive Officer | |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Pharmaceuticals: Major | Director of Finance/CFO Founder | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistics
International
| United States | 26 |
| United Kingdom | 17 |
| Germany | 3 |
| Singapore | 3 |
| Canada | 3 |
Sectoral
| Health Technology | 29 |
| Consumer Services | 19 |
| Health Services | 3 |
| Commercial Services | 2 |
| Finance | 2 |
Operational
| Director/Board Member | 702 |
| Corporate Officer/Principal | 280 |
| Independent Dir/Board Member | 163 |
| Chief Tech/Sci/R&D Officer | 87 |
| Chief Executive Officer | 74 |
Most connected contacts
| Insiders | |
|---|---|
| Cheok Peng Lim | 128 |
| Amir Nashat | 49 |
| Ed Mathers Mathers | 47 |
| Jack Nielsen | 38 |
| Otello Stampacchia | 37 |
| Trevor Jones | 36 |
| Mahendra Shah | 34 |
| Liam Ratcliffe | 32 |
| Kate Bingham | 31 |
| Nanna Liebach Lüneborg | 29 |
| David Ebsworth | 26 |
| Nilesh Kumar | 26 |
| Cameron Durrant | 25 |
| Axel Bolte | 23 |
| James Shannon | 22 |
- Stock Market
- Insiders
- Martin Edwards
- Company connections
